At first glance, these drugs look very similar. Yet the differences lie precisely in the points that weigh most heavily later: injection or tablet, registered use, rate of accrual and the likelihood of gastrointestinal complaints. As a result, a good comparison is less about popularity or price and more about what fits medically and practically. This only becomes really clear when the drugs are side by side.
Resources at a glance
Wegovy and Saxenda are registered for weight treatment; Ozempic and Rybelsus have a diabetes indication. All five call for a gradual build-up, as the starting phase often determines how well a drug can be sustained.
| Medium | Form | Mainline registration |
|---|---|---|
| Ozempic | Weekly injection | Type 2 diabetes |
| Wegovy | Weekly injection | Weight treatment |
| Mounjaro | Weekly injection | Depending on indication |
| Saxenda | Daily injection | Weight treatment |
| Rybelsus | Daily tablet | Type 2 diabetes |
By and large, it shows Mounjaro in trials saw the highest average weight loss, followed by semaglutide in the form of Wegovy. Saxenda comes out lower, but another profile may be a better fit medically or practically.
Rybelsus is particularly relevant when oral semaglutide enters the picture and is not a direct replacement for Wegovy. For all agents, nausea, diarrhoea and constipation are high on the list of common side effects, especially during accrual. Those who want to compare further will then benefit most from the medication summary for each drug with accrual, side effects and practical points of interest. Then it also becomes clear where the differences really lie.
Where the biggest differences really lie
Mounjaro operates at GLP-1 and GIP; Wegovy, Ozempic, Saxenda and Rybelsus work only on GLP-1. This difference affects not only effect expectation, but also the trade-off between compounding, tolerability and ease of use.
In the SURMOUNT studies, tirzepatide averaged 15-22% weight loss over 72 weeks, varying individually. Semaglutide for weight treatment sits roughly around 15% over 68 weeks in the STEP studies, while liraglutide comes out lower in the SCALE studies.
Agents containing the same substance are also not automatically interchangeable. Ozempic, Wegovy and Rybelsus contain semaglutide, but differ in dosage, form and registered use. Therefore, the comparison only has value if it is also clear why semaglutide is prescribed and within what medical framework. This is precisely where the real choice aid starts.
Considering the medical way to lose weight? Schedule a no-obligation consultation at WeightConsult. Do our own health check and contact us easily online
Which choice usually fits best
There is no universal best weight-loss drug. The choice usually follows from effect expectation, form of administration, dosage schedule and contraindication signals, not from brand recognition alone.
- Effect expectation only really counts when combined with tolerability and medical history.
- A weekly injection feels lighter for many people than daily prodding or swallowing, but that is not true for everyone.
- Sensitivity to nausea, delayed gastric emptying or previous gastrointestinal symptoms may limit the space.
- Signs such as pregnancy or childbearing, relevant endocrine risk factors and other history require physician assessment.
In the consulting room, an initial preference often shifts once previous side effects, practical feasibility and medical risks are juxtaposed. At WeightConsult, all four injectables are considered from the same medical consideration. The choice follows from contraindications, expected effectiveness and personal preference, not from price alone or what seems to be the easiest available at the time.
A tablet sometimes seems more accessible than an injection, but is not automatically the safest or most appropriate route. This shifts the question from which drug sounds strongest to which drug is medically appropriate.
Cost, reimbursement and follow-up step
Reimbursement of weight-loss medication is not standard and should be checked per policy and indication. Therefore, look not only at the price of the drug, but also at what is and is not included in a course, such as intake, medical assessment and guidance on accrual and side effects.
WeightConsult publishes a public fee schedule for each remedy so that the costs can be compared side by side without pretending that each course covers the same thing. Whether reimbursement is possible should always be checked with your own health insurer.
For orientation, a short shortlist helps: Wegovy as a semaglutide with weight indication, Mounjaro as a stronger candidate on average effect, Saxenda as a daily GLP-1 option, and Ozempic and Rybelsus only within the appropriate medical context. After that, it also usually becomes clear whether mainly in-depth per agent is needed, or a broader medical assessment first.
From comparison to responsible choice
The choice can only be properly justified when substance, form, registered use, effect expectation and tolerability have been weighed together. This often leaves one or two serious options that still need to be assessed for suitability, risks and feasibility. Those who already have a clear preferred direction can have it assessed in an intake; those who are still in doubt between several options would usually benefit more from a health check after which a doctor advises which direction is the best medical fit.